Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue by Freriksen, J.J.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/191930
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
Contents lists available at ScienceDirect
European Journal of Pharmaceutical Sciences
journal homepage: www.elsevier.com/locate/ejps
Placental disposition of the immunosuppressive drug tacrolimus in renal
transplant recipients and in ex vivo perfused placental tissue
J.J.M. Freriksena, D. Feyaertsb, P.H.H. van den Broeka, O.W.H. van der Heijdenc,
J. van Drongelenc, H.W. van Hamersveltd, F.G.M. Russela, R.G. van der Molenb, R. Greupinka,⁎
a Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
bDepartment of Laboratory Medicine, Radboud university medical center, Nijmegen, The Netherlands
c Department of Obstetrics and Gynecology, Radboud university medical center, Nijmegen, The Netherlands
d Department of Nephrology, Radboud university medical center, Nijmegen, The Netherlands
A R T I C L E I N F O
Keywords:
Ex vivo cotyledon perfusion
Placenta
Pregnancy
Renal transplantation
Tacrolimus
Pharmacokinetics
A B S T R A C T
Currently, tacrolimus is the most potent immunosuppressive agent for renal transplant recipients and is com-
monly prescribed during pregnancy. As data on placental exposure and transfer are limited, we studied tacro-
limus placental handling in samples obtained from renal transplant recipients. We found transfer to venous
umbilical cord blood, but particularly noted a strong placental accumulation. In patient samples, tissue con-
centrations in a range of 55–82 ng/g were found. More detailed ex vivo dual-side perfusions of term placentas
from healthy women revealed a tissue-to-maternal perfusate concentration ratio of 113 ± 49 (mean ± SEM),
underlining the placental accumulation found in vivo. During the 3 h ex vivo perfusion interval no placental
transfer to the fetal circulation was observed. In addition, we found a non-homogeneous distribution of tacro-
limus across the perfused cotyledons. In conclusion, we observed extensive accumulation of tacrolimus in pla-
cental tissue. This warrants further studies into potential eﬀects on placental function and immune cells of the
placenta.
1. Introduction
The incidence of pregnancy in the renal transplant patient popula-
tion is relatively high and increasing (OPTN/SRTR, 2014; McKay &
Josephson, 2006). Treatment with immunosuppressive drugs needs to
be continued during pregnancy to prevent graft rejection. Maintenance
treatment usually consists of a calcineurin inhibitor combined with a
glucocorticoid and/or an antimetabolite drug (Armenti et al., 2002).
The optimal use of the calcineurin inhibitors tacrolimus and cyclos-
porine A in pregnancy has been discussed in literature (Kim et al., 2015;
Liu et al., 2016).
Although>90% of all kidney transplant recipients in the US re-
ceive tacrolimus as part of their immunosuppressive regimen, resulting
in a considerable use during pregnancy, data on placental handling of
tacrolimus are scarce (OPTN/SRTR, 2014). Since pregnant women are
generally excluded from randomized controlled clinical trials because
of ethical, legal, and practical considerations, there is a paucity of
studies with respect to safety of drug use during pregnancy. Data on
fetal drug exposure are therefore limited to either case reports or
pharmacoepidemiological studies describing pregnancy outcome after
kidney transplantation under tacrolimus or cyclosporine A, as for in-
stance performed by the National Transplantation Pregnancy Registry
(NTPR) (Coscia et al., 2010). This large voluntary registry included
almost 2000 pregnancies in female kidney recipients in the period
1990–2010 in North America and reported that of all neonates born,
53% was premature and 46% had a low birthweight (< 2500 g), which
is signiﬁcantly higher than the general prevalence in the US in 2010 of
approximately 12% and 8%, respectively. In addition, 50–60% of all
neonates were delivered by caesarean section, compared to approxi-
mately 33% for general pregnancies (National Vital Statistics Report,
2012). In a large systematic review and meta-analysis of 4706 preg-
nancies in kidney transplant recipients, an increased rate of pregnancy
complications was also observed compared to the general population
(Deshpande et al., 2011). Nevertheless, the limited available literature
does not report any clinically relevant diﬀerences in pregnancy out-
come when comparing immunosuppressive drugs (Perales-Puchalt
et al., 2012).
Particularly in the absence of conclusive evidence on drug safety
from clinical trials, mechanistic pharmacological knowledge regarding
placental drug handling can help to decide which calcineurin inhibitor
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may be preferred during pregnancy. Tacrolimus (MW 804 g/mol, logP
3.3) and cyclosporine A (MW 1202 g/mol, logP 2.9) have been reported
to cross the placental barrier to a similar extent. For both drugs venous
umbilical cord concentrations have been reported to be lower than
maternal blood concentrations (Venkataramanan et al., 1988; Zheng
et al., 2013). However, when considering the safety of tacrolimus
during pregnancy, one should not only be concerned about placental
drug transfer, but also take a possible interference with placental
function into account. It is known that placental insuﬃciency may lead
to the pregnancy outcomes associated with the use of calcineurin in-
hibitors. Therefore, it possible that tacrolimus may indeed aﬀect pla-
cental function (Morgan, 2016). As placental drug exposure will drive
such potential adverse eﬀects, particularly more information on tacro-
limus tissue concentrations is needed.
To obtain more insight into the placental handling of tacrolimus
during pregnancy, we studied tacrolimus concentrations in placental
tissue samples from 6 renal transplant patients as well as in available
corresponding umbilical cord blood samples. In addition, we de-
termined placental accumulation and transfer of tacrolimus in an ex
vivo model using isolated dual-side perfusions of cotyledons from
healthy females.
2. Materials and methods
2.1. Collection of whole blood and placental tissue from renal transplant
patients
Pregnant renal transplant recipients (n=6) signed informed consent,
according to the Dutch Medical Research Involving Human Subjects Act
(WMO ﬁle number: 2014-232). Maternal peripheral blood was collected in
EDTA tubes during routine visits to the clinic to monitor tacrolimus trough
levels during pregnancy. Venous umbilical cord blood samples were avail-
able from 2 patients. Placentas were collected immediately after delivery
and pieces of approximately 1 cm3 of the central part of the placental bed
were stored at −80 °C until processing.
2.2. Conduction of placental perfusion experiments
The conduction of ex vivo placental perfusion studies with human tissues
was approved by the local ethics committee (ﬁle number: 2014-1397) and
an informed consent was signed which allowed use of placental tissue for ex
vivo studies, but no reporting of clinical data or pregnancy outcomes.
Placentas were collected from healthy pregnant women, who were not in-
fected with HIV, hepatitis B or hepatitis C. Women who had a retained
placenta or with a multiple pregnancy were also excluded. The perfusion
procedure was based on the method described by Schneider et al.
(Schneider et al., 1972; Schneider & Huch, 1985), with minor modiﬁcations
as reported previously (Schalkwijk et al., 2016). In brief, placentas were
collected immediately after delivery and time until perfusion was kept
below 45min. The perfusion medium consisted of Krebs-Henseleit buﬀer,
supplemented with 11.1mM glucose, 30 g/L human serum albumin (Al-
buman®, Sanquin, Nijmegen, the Netherlands) and 2500 IU/L heparin (LEO
Pharma, Amsterdam, The Netherlands). The medium was oxygenated with
95% O2/5% CO2, while being kept on 37 °C at a pH between 7.2 and 7.5.
An intact cotyledon was selected and a closed fetal circulation was re-
established by cannulation of the matching vein and artery (6mL/min).
Subsequently, four cannulas were inserted through the maternal decidual
plate into the intervillous space, resulting in an inﬂow of 12mL/min.
Medium ﬂowing from the intervillous space into the perfusion chamber was
recirculated via the maternal reservoir ensuring a closed system. In a pre-
perfusion period, both circulations were initially left open in order to wash
out residual blood. Subsequently, at the start of the experiment, maternal
and fetal circulations were closed and 10 ng/mL tacrolimus (Sigma-Aldrich,
Zwijndrecht, The Netherlands) was added to the closed maternal circula-
tion, which had a volume of 200mL. After 10, 30, 45, 60, 90, 120, 150 and
180min of perfusion, samples were taken from both the maternal and fetal
reservoir and stored at−20 °C until analysis. At the end of the experiment,
the perfused cotyledon was excised from the remainder of the placenta,
snap frozen in liquid nitrogen and stored at−80 °C until further use. To test
for adherence of tacrolimus to our perfusion system a control perfusion was
conducted in the absence of placental tissue.
For every placental perfusion, control substances were included to
determine whether the placental capillary bed remained intact
throughout the period of perfusion and to conﬁrm overlap of the fetal
and maternal circulation. Because of its size, FITC-dextran (molecular
weight: 40 kDa) is expected not to cross the placental barrier after ad-
dition to the fetal circulation (36mg/L), and therefore served as a
marker for integrity of the fetal capillary bed. Antipyrine (molecular
weight: 188 Da, logP: 0.38) was added to the maternal circulation
(100mg/L). It undergoes rapid passive diﬀusion across the placental
barrier and was used to conﬁrm overlap of the maternal and fetal cir-
culation. These markers have been used previously in placental perfu-
sion studies by Myllynen et al., Mathiesen et al. and Schalkwijk et al.
(Schalkwijk et al., 2016; Myllynen et al., 2010; Mathiesen et al., 2010).
2.3. Analysis of antipyrine and FITC-dextran concentrations in perfusate
samples
Samples were processed according to the method of Brodie et al.
after which antipyrine levels could be measured at 350 nm using a plate
reading spectrophotometer (Brodie et al., 1949). A Fluorescence Multi-
well Plate Reader (PerkinElmer, Ex 485 nm/Em 530 nm) was used to
determine the FITC-dextran level in the maternal and fetal reservoir
over time. The experiment was considered successful when the anti-
pyrine maternal-to-fetal concentration ratio at the end of the perfusion
was< 1.25 (i.e. good overlap of maternal and fetal circulation), the
maternal-to-fetal concentration ratio of FITC-dextran was<0.03, and
volume loss from the fetal circulation did not exceed 3mL/h during
180min of perfusion (conﬁrmed integrity of placental capillary bed).
2.4. Analysis of tacrolimus concentration in whole blood, tissue and
perfusate samples
The tacrolimus assay in whole blood is based on validated UPLC–tandem
mass spectrometry (Hoogtanders et al., 2007) and is used for therapeutic drug
monitoring purposes in our medical center. To determine the tacrolimus
concentration in placental tissue of renal transplant patients and in placental
tissue after 180min of perfusion, homogenates were made to allow sub-
sequent LC-MS/MS analysis, by homogenizing 1 part of tissue in 4 parts of
Krebs-Henseleit buﬀer. Rapamycin (Sigma-Aldrich, Zwijndrecht, The Neth-
erlands) was used as internal standard. To precipitate proteins, methanol was
added to perfusate and homogenate samples. Following ultrasoniﬁcation
(5min) and subsequent centrifugation (12,000 g for 3min), supernatant was
used to quantify tacrolimus. Tacrolimus levels were determined by LC-MS/
MS analysis, using an Acquity UPLC system (Waters, Milford, MA, USA)
coupled to a Xevo TQ-S (Waters) triple quadrupole mass spectrometer. The
elution gradient was as follows: 0min, 55% B; 0.6–0.7min, 70% B;
0.7–0.8min, 90% B; 0.8–2.3min 100% B and 2.3–2.5min 55% B. The mo-
bile phase consisted of solvent A (1mM NH4F+0.1% formic acid in H2O)
and solvent B (1mM NH4F+0.1% formic acid in MeOH). The following
MRM transitions were used: for tacrolimus m/z 821.8 (parent ion) to m/z
768.7 and 786.8 (both product ions), for rapamycinm/z 931.9 (parent ion) to
m/z 864.9 and 882.8 (both product ions). The detection limit of the assay was
0.24 nM. Data were analyzed using Graphpad Prism 5.03 (Prism, Graphpad
software Inc., San Diego, USA) and results are presented as mean ± SEM.
3. Results
3.1. In vivo placental handling of tacrolimus in renal transplant patients
Patient characteristics of the 6 women participating in this part of
our study can be found in Table 1. Based on analysis of venous
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umbilical cord concentrations as well as corresponding placental
tissue concentrations, placental handling of tacrolimus could be as-
sessed in vivo. The maternal Ctrough level at the last sampling time
point before delivery varied between 2.9 and 7.6 ng/mL. In 2 cases,
venous umbilical cord blood concentration were recorded in patient
records, being 4.8 and 6.2 ng/mL, which is indicative of placental
transfer of tacrolimus. A placental tissue concentration ranging be-
tween 55 and 82 ng/g demonstrated tacrolimus accumulation within
the organ (Table 2).
3.2. Ex vivo placental perfusion experiments
A total of four out of eight perfusion experiments with placentas of
healthy women met the quality control criteria as explained above;
three from vaginal deliveries and one from an elective caesarean sec-
tion. As can be seen in Fig. 1A, the antipyrine concentrations equili-
brated in both circulations. Upon addition to the maternal circulation, a
mean maternal-to-fetal concentration ratio of 1.07 ± 0.04 for anti-
pyrine was observed. This is in accordance with good passive diﬀusion
across the placental barrier, indicating overlap of the maternal and fetal
circulations. Integrity of villous structures was conﬁrmed by the poor
placental passage (maternal-to-fetal concentration ratio of< 0.03) of
FITC-dextran (Fig. 1B). For both the maternal and fetal reservoir, pH
and volume loss were within the predeﬁned required ranges
(pH 7.2–7.5, volume loss< 3mL/h).
After addition of tacrolimus (10 ng/mL) to the maternal circula-
tion, maternal perfusate levels decreased to 1.9 ± 0.4 ng/mL at
t=180 min, while tacrolimus remained undetectable in the fetal
reservoir (Fig. 2). The poor placental transfer from maternal to fetal
circulation in the investigated perfusion interval and absence of the
drug in the fetal circulation suggested placental retention of tacro-
limus. Comparison of the tacrolimus concentration in placental tissue
with tacrolimus concentration in maternal perfusate at the end of the
experiment, indeed revealed a tissue-to-maternal perfusate con-
centration ratio of 113 ± 49, as shown in Table 3. Interestingly, our
ex vivo perfusion studies also demonstrated that tacrolimus was not
distributed homogeneously across the perfused cotyledon (Supple-
mentary Table S1). The measured tissue concentrations diﬀered up to
a factor 19 in a series of samples taken from diﬀerent locations in the
same cotyledon. Nevertheless, in all samples obtained in the ex vivo
perfusions, placental tissue concentrations exceeded maternal and
fetal perfusate concentrations.
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Table 2
Tacrolimus concentrations in maternal whole blood, placental tissue and ve-
nous umbilical cord blood of renal transplant recipients. The reported maternal
tacrolimus concentration is the last Ctrough level measured before delivery and
derived from patient records. Hence sampling of maternal blood was not at the
time of delivery but at varying times prior to delivery.
Patient Maternal Ctrough level
before delivery (ng/mL)
Placental tissue
concentration (ng/g)
as mean ± SEM
Venous umbilical cord
blood concentration
(ng/mL)
#1 4.2 55 ± 3 –
#2 7.6 68 ± 19 –
#3 3.9 82 ± 6 –
#4 6.6 75 ± 2 –
#5 2.9 62 ± 2 6.2
#6 4.0 82 ± 1 4.8
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4. Discussion
We observed a substantial, > 10-fold accumulation of tacrolimus in
placentas obtained from both renal transplant recipients as well as in ex
vivo perfusion experiments using placental tissue from healthy females.
To our knowledge, tacrolimus concentrations in placentas from renal
transplant recipients have not been reported before. In a study per-
formed by Jain et al., who focused on liver transplant patients, a 3-fold
higher tacrolimus concentration in placental tissue compared to ma-
ternal plasma levels was reported (Jain et al., 1997). In our study we
found a much higher degree of accumulation in placental tissue samples
from exposed patients. This could be due to diﬀerences in placental
disposition between renal and liver transplant patients, but possibly
also because of diﬀerences in methods of analysis, tissue preservation or
sampling, which were only brieﬂy described by the authors and did not
allow us to compare these aspects between the studies. As tacrolimus is
a drug with a high volume of distribution, it is likely that tissue accu-
mulation of this drug is not limited to the placenta. Indeed, tissue dis-
tribution studies in rats showed accumulation within the heart, lung
and spleen (Venkataramanan et al., 1990), while also accumulation was
noted in liver and kidney biopsies obtained from liver and kidney
transplant patients (Noll et al., 2013; Capron et al., 2007). Nevertheless,
we now describe that in renal transplant patients, signiﬁcant exposure
of the placenta clearly takes place, indicating that this organ may be
prone to tacrolimus-induced toxicity as well.
In contrast to our observations in short-term perfusion experiments
that did not show detectable tacrolimus levels in the fetal circulation,
analysis of venous umbilical cord blood samples indicated that in vivo
fetal exposure to tacrolimus does occur. This discrepancy could mean
that the extensive placental binding of tacrolimus that contributes to
the placental retention in the ex vivo studies, may have become satu-
rated upon chronic exposure in the clinical setting. Saturation of
binding capacity would result in an increase in unbound tacrolimus
concentrations within the placenta and therefore a stronger driving
force for diﬀusion from the placenta to the fetal circulation. To further
study whether saturation of tissue binding plays a role, ex vivo placental
perfusion experiments could be performed with placentas from renal
transplant recipients that have been chronically exposed to tacrolimus
in vivo. In this case, an increased placental transfer to the fetal circu-
lation would be expected to occur.
Our in vivo data demonstrated that the venous umbilical cord blood
concentrations were somewhat higher than the maternal Ctrough levels.
However, because the sampling times of venous umbilical cord blood
and maternal blood did not match in our observational study, it was not
possible to give an accurate estimate of the maternal tacrolimus level
around the time of delivery, and hence calculate an exact placental
transfer ratio. Zheng et al. collected maternal blood immediately after
delivery and observed venous umbilical cord blood concentrations in
exposed pregnant patients that were 71 ± 18% (range 45–99%) of
maternal concentrations (Zheng et al., 2013).
As tacrolimus displays extensive erythrocyte binding in vivo, but no
erythrocytes were added to the ex vivo perfusion buﬀer, the total ta-
crolimus concentration of 10 ng/mL used in this study probably results
in higher free concentrations than present in whole blood of renal
transplant recipients (Staatz & Tett, 2004). Still, physiological albumin
concentrations were present in the ex vivo perfusion buﬀer, as well as
some circulating erythrocytes since they cannot be washed out com-
pletely from the placenta. We did not measure the ultimate unbound
Fig. 1. Placental transfer of the control molecules antipyrine and FITC-dextran. Concentration–time proﬁle of (A) antipyrine (100mg/L) and (B) FITC-dextran
(36mg/L) in the maternal (open circles) and fetal circulation (squares), based on four successful experiments during 180min of perfusion. Data are depicted as
mean ± SEM.
Fig. 2. Placental transfer of tacrolimus. Concentration–time proﬁle of tacro-
limus (10 ng/mL) in the maternal (open circles) and fetal circulation (squares),
based on four successful experiments during 180min of perfusion. Data are
depicted as mean ± SEM.
Table 3
Tacrolimus concentrations in perfusate samples and perfused tissue after pla-
cental perfusion experiments. Placental tissue-to-maternal perfusate con-
centration ratio was calculated based on the tacrolimus concentration in ma-
ternal perfusate at the end of a perfusion and the perfused placental tissue
concentration. Results are depicted as mean ± SEM.
Perfusion Maternal perfusate
concentration at
t=180min (ng/mL)
Placental tissue
concentration (ng/g)
as mean ± SEM
Placental tissue-to-
maternal perfusate
concentration ratio
#1 1.8 54 ± 8 31
#2 2.1 138 ± 85 65
#3 2.8 287 ± 103 102
#4 0.9 236 ± 76 253
Mean 1.9 179 113
SEM 0.4 52 49
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concentrations in the ex vivo experiments, but this could be considered
relatively high. On the other hand, it should be noted that the tacro-
limus fraction unbound in vivo also increases during pregnancy (Zheng
et al., 2012). After addition of tacrolimus to the maternal perfusate, we
found that rapid extraction occurred to the placenta, while also some
adherence to components of the perfusion system was observed. Despite
the high unbound tacrolimus exposure in the maternal perfusate and
therefore also a large driving force for passive placental transfer, the
amount of drug transported to the fetal circulation still remained neg-
ligible during 180min of perfusion, further pointing to a high tacro-
limus binding capacity of placental tissue.
Information about diﬀerences in placental accumulation and
transfer between diﬀerent calcineurin inhibitors may aid in the deci-
sion-making process of the drug of ﬁrst choice during pregnancy.
Nandakumaran et al. studied ex vivo placental transfer of cyclosporine A
in a perfusion set-up and reported< 5% passage along with placental
accumulation of cyclosporine A. This is in line with our ﬁndings with
tacrolimus (Nandakumaran & Eldeen, 1990). The question now arises
to which extent placental accumulation of either cyclosporine A and
tacrolimus is causally linked to placental toxicity and how this relates to
the adverse pregnancy outcomes reported in literature. Considering the
vasoconstrictive eﬀects of calcineurin inhibitors as well as their toxic
eﬀects on the kidney and pancreatic beta cells, potential cytotoxic ef-
fects on the placental level might be expected as well (Hoskova et al.,
2017; Ozbay et al., 2011). Placental cytotrophoblasts, syncytiotropho-
blasts and endothelial cells may be diﬀerentially aﬀected in the face of
the high concentrations we described here. Moreover, since the immune
system is crucial for proper placentation, placental tissue accumulation
of calcineurin inhibitors could also interfere with placental lymphocyte
function and maturation, leading to pregnancy complications (Saito
et al., 2010). Finally, rat embryo culture experiments showed that ta-
crolimus was more likely to induce apoptosis and cause more mor-
phological abnormalities than cyclosporine A (Fazliogullari et al.,
2016). Translation of the data from such studies to a toxicological risk
for adverse placental drug eﬀects in human is still diﬃcult, because of
species diﬀerences and because eﬀects were not linked to the placental
drug concentrations that were reached. We propose to combine our
data on human placental drug concentrations with dose-response data
for eﬀects of tacrolimus on key placental physiological processes mea-
sured in vitro or ex vivo in human placental cells and tissues. This will
help to further delineate risks of adverse placental eﬀects of calcineurin
inhibitors during pregnancy. In this respect, physiologically-based
pharmacokinetic modeling approaches can also provide an opportunity
to further advance our understanding of the link between placental
pharmacokinetics and pharmacodynamics of immunosuppressive drugs
(Schalkwijk et al., 2017).
We conclude that tacrolimus accumulates in placental tissue of renal
transplant recipients treated with this drug, which is in line with ob-
servations in the ex vivo perfused human cotyledon. The build-up of a
placental reservoir of tacrolimus in renal transplant patients warrants
further studies into potential adverse pharmacological and im-
munological eﬀects on placental function.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ejps.2018.04.017.
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